CapsoVision (CV) Liabilities and Shareholders Equity (2024 - 2026)
CapsoVision (CV) posted Liabilities and Shareholders Equity of $18.2 million for Q4 2025, down 29.22% sequentially from $25.7 million in Q3 2025, and up 8.1% YoY from $16.8 million in Q4 2024.
CapsoVision (CV) Liabilities and Shareholders Equity (2024 - 2026) Analysis & Trends
CapsoVision has reported Liabilities and Shareholders Equity for 2 years, with the latest figure at $18.2 million in Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 8.1% year-over-year to $18.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $70.2 million (changed N/A YoY) and the FY2025 annual result came in at $18.2 million, up 8.1% from the prior year.
- Liabilities and Shareholders Equity retreated to $18.2 million in Q4 2025 per CV's latest filing, from $25.7 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $25.7 million in Q3 2025 and troughed at $9.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 10.74 Bn |
| 10 | CapsoVision | 295.13 Mn | 286.05 Mn | 1.87 Mn | 18.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.57 Mn |
| Dec 31, 2025 | 18.16 Mn |
| Sep 30, 2025 | 25.66 Mn |
| Jun 30, 2025 | 9.55 Mn |
| Dec 31, 2024 | 16.80 Mn |